Beta Bionics Inc

BBNX remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs. Price is extended into overbought territory near prior resistance and shows minor exhaustion signals, making short-term timing unfavorable. We defer entries and look for a selective pullback into the rising 9/21 EMA support zone. A decisive close below the 21 EMA on increased volume would invalidate the medium-term bullish bias and require reassessment.

• ↑Q1 net sales reached $27.6M, up 57% YoY, driving revenue momentum.
• ↑Gross margin expanded to 59.5%, up ~400bps YoY via high-margin pharmacy channel.
• ↓Operating expenses rose to $40.7M, a 47% YoY increase, pressuring cash burn.